{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:54Z","timestamp":1790913714032,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12288-024-01769-z","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T18:01:46Z","timestamp":1713895306000},"page":"573-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6842-8613","authenticated-orcid":false,"given":"Gaurav","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"3","key":"1769_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0971-5851.123711","volume":"34","author":"S Bansal","year":"2013","unstructured":"Bansal S, Prabhash K, Parikh P (2013) Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol 34(3):154\u2013158","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"1","key":"1769_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JGO.2015.002667","volume":"3","author":"P Ganesan","year":"2017","unstructured":"Ganesan P, Kumar L (2017) Chronic myeloid leukemia in India. J Glob Oncol 3(1):64\u201371","journal-title":"J Glob Oncol"},{"issue":"5","key":"1769_CR3","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8(5):935\u2013942","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1769_CR4","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","volume":"108","author":"L Roy","year":"2006","unstructured":"Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O\u2019Brien S, So C, Massimini G, Guilhot F (2006) Survival advantage from imatinib compared with the combination interferon-\u03b1 plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108(5):1478\u20131484","journal-title":"Blood"},{"issue":"9","key":"1769_CR5","first-page":"1981","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, J Am Soc Hematol 119(9):1981\u20131987","journal-title":"Blood, J Am Soc Hematol"},{"issue":"11","key":"1769_CR6","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Rosee P, M\u00fcller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11):2190\u20132196","journal-title":"Leukemia"},{"issue":"10","key":"1769_CR7","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D et al (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767\u20131773","journal-title":"Leukemia"},{"issue":"19","key":"1769_CR8","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las RJ, Trougakos IP, Sarmento Ribeiro AB (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers 13(19):4820","journal-title":"Cancers"},{"issue":"9305","key":"1769_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N Von Bubnoff","year":"2002","unstructured":"Von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359(9305):487\u2013491","journal-title":"Lancet"},{"issue":"9","key":"1769_CR10","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S et al (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9):3472\u20133475","journal-title":"Blood"},{"issue":"2","key":"1769_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B et al (2002) Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117\u2013125","journal-title":"Cancer Cell"},{"key":"1769_CR12","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","volume":"98","author":"FE Nicolini","year":"2013","unstructured":"Nicolini FE, Ibrahim AR, Soverini S et al (2013) The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 98:1510\u20131516","journal-title":"Haematologica"},{"key":"1769_CR13","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242\u20132249","journal-title":"Blood"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R et al (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib resistant BCR\/ABL mutants. J Clin Oncol 27:469\u2013471","journal-title":"J Clin Oncol"},{"key":"1769_CR15","unstructured":"O\u2019Brien S, Abboud CN, Akhtari M et al Clinical Practice Guidelines in Oncology.Chronic myelogenous leukemia, Version 2.2014, National Comprehensive Cancer Network (NCCN). Available from:\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4234105\/. Accessed\u00a001\/03\/2024"},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u201384","journal-title":"Blood"},{"key":"1769_CR17","doi-asserted-by":"publisher","first-page":"ix95","DOI":"10.1093\/annonc\/mdz427.013","volume":"30","author":"K Mishra","year":"2019","unstructured":"Mishra K, Yanamandra U, Shukla A, Pramanik SK, Kapoor R, Das S (2019) Risk stratification of CML-CP in a real-world scenario, comparison of SHE with rate of fall of BCR\/ABL. Ann Oncol 30:ix95","journal-title":"Ann Oncol"},{"issue":"2","key":"1769_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Huang XJ, Jiang Q (2022) Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia 36(2):482\u2013491","journal-title":"Leukemia"},{"key":"1769_CR19","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3109\/10428191003729741","volume":"51","author":"P Sharma","year":"2010","unstructured":"Sharma P, Mohanty S, Kochupillai V et al (2010) Mutations in ABL kinase domain are associated with inferior progression free survival. Leuk Lymphoma 51:1072\u20131078","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1769_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/0971-5851.123736","volume":"34","author":"G Babu","year":"2013","unstructured":"Babu G (2013) Report of patients with chronic myeloid leukemia Kidwai memorial institute of oncology Bangalore over 15 years. Indian J Med Paediatr Oncol 34(3):196\u2013198","journal-title":"Indian J Med Paediatr Oncol"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4103\/0377-4929.120369","volume":"56","author":"SK Sinha","year":"2013","unstructured":"Sinha SK, Sinha S, Mandal PK et al (2013) A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers. Indian J Pathol Microbiol 56:216\u2013220","journal-title":"Indian J Pathol Microbiol"},{"issue":"11","key":"1769_CR22","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3109\/10428194.2016.1157868","volume":"57","author":"N Patkar","year":"2016","unstructured":"Patkar N, Ghodke K, Joshi S, Chaudhary S, Mascerhenas R, Dusseja S, Mahadik S, Gaware S, Tembhare P, Gujral S, Kabre S (2016) Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. Leuk Lymphoma 57(11):2653\u20132660","journal-title":"Leuk Lymphoma"},{"key":"1769_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12288-016-0755-y","volume":"33","author":"AK Tripathi","year":"2017","unstructured":"Tripathi AK, Verma SP, Kumar N (2017) Mutation analysis in chronic myeloid leukemia patient in chronic phase on imatinib having delayed achievement of milestones or loss of response. Indian J Hematol Blood Transfus 33:316\u2013320","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"03","key":"1769_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.4103\/ijmpo.ijmpo_115_17","volume":"38","author":"PK Chaitanya","year":"2017","unstructured":"Chaitanya PK, Kumar KA, Stalin B, Sadashivudu G, Srinivas ML (2017) The Role of Mutation Testing in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Failure and Their Outcomes after Treatment Modification: Single-institutional Experience Over 13 Years. Indian J Med Paediatr Oncol 38(03):328\u2013333","journal-title":"Indian J Med Paediatr Oncol"},{"key":"1769_CR25","first-page":"v444","volume":"30","author":"NR Palukuri","year":"2019","unstructured":"Palukuri NR, Stalin B, Chennamaneni R, Prasad SK, Konatam ML, Gundeti S (2019) Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation. Ann Oncol 30:v444","journal-title":"Ann Oncol"},{"issue":"2","key":"1769_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/jpgm.JPGM_781_20","volume":"68","author":"KB Bommannan","year":"2022","unstructured":"Bommannan KB, Naseem S, Binota J, Varma N, Malhotra P, Varma S (2022) Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience. J Postgrad Med 68(2):93","journal-title":"J Postgrad Med"},{"key":"1769_CR27","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.1007\/s13277-014-1926-9","volume":"35","author":"S Kagita","year":"2014","unstructured":"Kagita S, Uppalapati S, Jiwatani S et al (2014) Incidence of BCR-ABL kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol 35:7187\u20137193","journal-title":"Tumour Biol"},{"issue":"7","key":"1769_CR28","doi-asserted-by":"publisher","first-page":"e1376","DOI":"10.1002\/hsr2.1376","volume":"6","author":"C Benjamin","year":"2023","unstructured":"Benjamin C, Murugan S, Hoosen S, Rapiti N (2023) Chronic myeloid leukemia kinase domain mutations: A retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa. Health Sci Rep 6(7):e1376","journal-title":"Health Sci Rep"},{"issue":"1","key":"1769_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/10428194.2018.1473573","volume":"60","author":"Y Erbilgin","year":"2019","unstructured":"Erbilgin Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, Elverdi T, Firtina S, Tasar O, Mercan S, Sisko S, Khodzhaev K, Ongoren S (2019) Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leuk Lymphoma 60(1):200\u2013207","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1769_CR30","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1002\/cam4.2410","volume":"8","author":"G Etienne","year":"2019","unstructured":"Etienne G, Dulucq S, Huguet F, Schmitt A, Lascaux A, Hayette S, Fort MP, Sujobert P, Bijou F, Morisset S, Tavitian S (2019) Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Med 8(11):5173","journal-title":"Cancer Med"},{"key":"1769_CR31","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of ABL kinase domain mutations in imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA working party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374\u20137379","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1769_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","volume":"20","author":"FE Nicolini","year":"2006","unstructured":"Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T (2006) Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi (\u03d5)-LMC GROUP). Leukemia 20(6):1061\u20131066","journal-title":"Leukemia"},{"issue":"12","key":"1769_CR33","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3109\/10428190903332486","volume":"50","author":"P Markose","year":"2009","unstructured":"Markose P, Chendamarai E, Balasubramanian P, Velayudhan SR, Srivastava VM, Mathews V, George B, Viswabandya A, Srivastava A, Chandy M (2009) Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leuk Lymphoma 50(12):2092\u20132095","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1769_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/10428190903437629","volume":"51","author":"S Rajappa","year":"2010","unstructured":"Rajappa S, Mallavarapu KM, Gundeti S, Roshnipaul T, Jacob RT, Digumarti R (2010) Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. Leuk Lymphoma 51(1):79\u201384","journal-title":"Leuk Lymphoma"},{"issue":"03","key":"1769_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4103\/0971-5851.123748","volume":"34","author":"S Srivastava","year":"2013","unstructured":"Srivastava S, Dutt S (2013) Imatinib mesylate resistance and mutations: An Indian experience. Indian J Med Paediatr Oncol 34(03):213\u2013220","journal-title":"Indian J Med Paediatr Oncol"},{"key":"1769_CR36","doi-asserted-by":"publisher","first-page":"ix85","DOI":"10.1093\/annonc\/mdv526.26","volume":"26","author":"S Mukhopadhyay","year":"2015","unstructured":"Mukhopadhyay S, Dasgupta S, Mitra P, Bose CK, Gharami FH, Mukhopadhyay A (2015) 310P Correlation of different mutations with drug resistance in chronic myeloid leukemia in Indian perspective. Ann Oncol 26:ix85","journal-title":"Ann Oncol"},{"key":"1769_CR37","doi-asserted-by":"crossref","unstructured":"Majumdar A, Katara R, Mishra A, Gupta A, Sharma DK, Srivastava AK, Sharma S, Jaiswal A, Dixit M, Kumar V, Kumar S (2022) A Retrospective Analysis of BCR-ABL1 Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory.\u00a0South Asian J\u00a0Cancer","DOI":"10.1055\/s-0042-1757911"},{"issue":"10","key":"1769_CR38","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/ajh.27037","volume":"98","author":"FG Haddad","year":"2023","unstructured":"Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP (2023) Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre-and post-ponatinib era. Am J Hematol 98(10):1619\u20131626","journal-title":"Am J Hematol"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-024-01769-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T22:05:57Z","timestamp":1729980357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-024-01769-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s12288-024-01769-z","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}